Myasthenia gravis (MG) is a rare autoimmune neuromuscular disorder that causes fluctuating muscle weakness, often affecting daily activities like speaking, walking, or even breathing. While symptoms ...

What were the most significant improvements seen in the Myasthenia Gravis-Activities of Daily Living and Quantitative ...

Weekly subcutaneous gefurulimab delivered early is linked to lasting symptom improvement in patients with generalized ...

The MarketWatch News Department was not involved in the creation of this content. New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug ...

The first FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ Nipocalimab demonstrated a sustained reduction in ...

Marks first FDA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies Filing based on the Phase 3 ...

First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied About 10% ...

First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and substantial reduction in immunoglobulin ...

The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...

Myasthenia gravis is a chronic autoimmune disorder that disrupts nerve-to-muscle signaling, causing weakness. Modern treatments help many people live typical life spans and enter remission.

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or ...

This content was sponsored by argenx. Tom is a real patient who was on treatment when he shared his personal experiences. Individual results may vary. Tom Hopkins served with the Marine Corps in ...